The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...
Penmenvy is a combination of GSK's already-approved vaccines Bexsero and Menveo, which together brought in more than £1.4 billion (around $1.8 billion) in sales last year with double-digit growth ...
Mar. 5, 2025 — A live-attenuated tuberculosis (TB) vaccine candidate in development elicits a much more balanced and effective immune response compared to the existing vaccine used across much ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results